Alzeca Biosciences company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series A | Alive

Total Raised


Last Raised

$11M | 5 yrs ago

About Alzeca Biosciences

Alzeca Biosciences develops imaging compounds to diagnose Alzheimer's disease at the earliest stages. Early detection of Alzheimer's is critical as disease pathology begins to accumulate 10+ years prior to cognitive onset of the disease. As a result, early detection of Alzheimer's pathology offers the patient an opportunity to take counteractive measures at a point where the disease may still be treatable.

Alzeca Biosciences Headquarter Location

1800 Bering Drive #430

Houston, Texas, 77057,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Alzeca Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Alzeca Biosciences is included in 3 Expert Collections, including Medical Devices.


Medical Devices

7,913 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health Monitoring & Diagnostics

2,394 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance


Health IT

7,900 items

Alzeca Biosciences Patents

Alzeca Biosciences has filed 4 patents.

The 3 most popular patent topics include:

  • Membrane biology
  • Neurological disorders
  • Proteins
patents chart

Application Date

Grant Date


Related Topics




Membrane biology, Phospholipids, Dosage forms, Drug delivery devices, Psychiatric diagnosis


Application Date


Grant Date



Related Topics

Membrane biology, Phospholipids, Dosage forms, Drug delivery devices, Psychiatric diagnosis



Latest Alzeca Biosciences News

Alzeca Biosciences Closes $11 Million Series A Financing

Aug 17, 2017

ONL Therapeutics closes .25 million in Series A funding Alzeca Biosciences, Inc., an early-stage healthcare diagnostic company focused on developing novel MRI-based targeted imaging agents for the early diagnosis of Alzheimer’s disease and other neurodegenerative disorders, announced today that it has closed an $11 million Series A financing. With the transaction, Peter J. Werth, Jr., President and Chief Executive Officer of Chemwerth, Inc., and Navneet Puri, Ph.D., Founder and Chief Executive Officer of Nevakar, LLC, joined the Alzeca Board of Directors. Alzeca will use the funds to advance the development of its ADx nanoparticle, the first magnetic resonance imaging (MRI) contrast agent targeting amyloid plaques, through Phase 1 human clinical trials. Amyloid is one of the key brain proteins associated with Alzheimer’s disease and other neurodegenerative conditions. Additionally, the new funding will enable Alzeca to accelerate development of MRI-based imaging agents targeting other abnormal brain proteins associated with Alzheimer’s disease and other causes of dementia, including chronic traumatic encephalopathy (CTE). “We are very pleased to complete this significant round of financing with experienced private investors who have a firm commitment to advancing these urgently needed healthcare innovations in Alzheimer’s disease and other types of dementia,” said Carlo Medici, CEO of Alzeca. Until now, the accuracy of diagnosis in Alzheimer’s disease has been very low. Recent research has suggested that PET (positron-emission tomography) brain imaging of amyloid plaque deposition could improve dementia diagnosis in up to two-thirds of patients. However, PET imaging is costly, not widely available to healthcare providers, and subjects patients to high doses of radiation (equivalent to up to 70 chest x-rays). By comparison, the successful development of ADx would make early and reliable Alzheimer’s diagnostic testing available worldwide, using MRI scanning technology that is broadly accessible, at far lower cost and without any radiation exposure. Detection of Alzheimer’s disease a decade or more before symptoms appear would revolutionize its treatment and vastly improve the efficiency of clinical trials for new therapies by identifying appropriate candidates for participation and monitoring their response to new drugs. “The ability to diagnose neurodegenerative diseases such as Alzheimer’s years before serious cognitive impairment manifests, so as to potentially intervene therapeutically at an early stage in the disease process, is a significant healthcare challenge,” said Mr. Werth. “We are excited to partner with Alzeca because its promising MRI brain imaging agents offer great potential not only to advance the early diagnosis of such conditions but also to aid in monitoring patient response to treatment both during drug development and in the clinic.” “Alzeca is addressing a critical healthcare need and has assembled a highly experienced management team composed of world-renowned experts in diagnostic imaging, clinical neurosciences and commercial pharmaceutical and biomedical development,” said Dr. Puri. “Bringing novel diagnostic approaches and more accurate biomarkers to address the challenges of Alzheimer’s disease and other neurodegenerative diseases is a worthy cause and will benefit millions of patients, caregivers and healthcare providers. I am very happy to support them and invest in this endeavor.” Biographies of the New Alzeca Board Members Peter J. Werth, Jr. founded Chemwerth, Inc., in 1982 and serves as its Chief Executive Officer and President. A pioneer in developing and supplying generic active pharmaceutical ingredients, Mr. Werth has committed his professional life to improving global access to high-quality, affordable generic pharmaceuticals. Mr. Werth is also a recognized philanthropist, establishing the Werth Family Foundation in 2001 to support higher education, children and human services, the arts and the environment. Navneet Puri, PhD, is Founder and Chief Executive Officer of Nevakar, LLC. After earning his MS and PhD in Pharmaceutics, Dr. Puri worked for several years at Baxter Healthcare Corp and Amgen Inc. in the areas of parenteral drug development and drug delivery. Dr. Puri founded InnoPharma, Inc., in 2005 with a focus on developing complex generic pharmaceuticals of sterile injectable dosage forms. The company was acquired by Pfizer in 2014. Dr. Puri received the Smart CEO award from Future 50 magazine in January 2015. He was also awarded an E&Y Entrepreneur of the Year award from the state of New Jersey in June 2015. About Alzeca Biosciences, Inc. Alzeca Biosciences is an early-stage company focused on developing novel, proprietary, targeted MRI imaging agents for the early diagnosis of Alzheimer’s disease and other neurodegenerative disorders. The company’s proprietary technology is based on nanoparticles that specifically bind to abnormal proteins that accumulate in the brain years before significant cognitive symptoms appear. Alzeca’s imaging agents would provide a new opportunity for safe, cost-effective, and widely available diagnosis and screening for these important diseases. Alzeca Biosciences is based in Houston. For more information on the company, please visit our website at . View source version on Alzeca Biosciences, Inc.

Alzeca Biosciences Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Alzeca Biosciences Rank

You May Also Like

NeuroVision Imaging

NeuroVision Imaging is developing retinal imaging technology for early detection and monitoring of Alzheimer's disease.


Cymedix develops assays for the early detection of mitochondrial diseases such as Alzheimer's disease. Earlier detection enables earlier therapy, and development of personalized medicine solutions.

Darmiyan Logo

Darmiyan develops fully automated proprietary software that inputs human brain MRIs and produces maps that detect Alzheimer's disease up to fifteen years before symptoms. Its mission is to create a fast, non-invasive, inexpensive, precise, and globally accessible tool for brain health screening and monitoring. Darmiyan's technology provides a platform for presymptomatic diagnosis of neurodegenerative disorders, with precise quantification and localization of microscopic abnormality in the brain.

Neurotrack Technologies

Neurotrack is a digital medicine solution for Alzheimer's disease, giving people direct access to the scientifically validated digital diagnostic and therapeutic to delay or prevent memory health conditions.


ADispell is a pharmaceutical development company with technology related to Alzheimers, cognition-loss disease, drug addiction, and other CNS areas. Three lead compounds have been identified for this platform technology and in vivo experiments have produce clear evidence of improved cognition and learning in impaired animals. Our team will continue pre-clinical work with the goal of licensing our development to a pharma partner. These deals have closed for $100s of millions of dollars.

Cytox Logo

Cytox is developing a diagnostic test and therapeutic cures for Alzheimer's Disease. The company is a university spin-out based on academic research into the role of the cell cycle in neuro-degenerative diseases.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.